We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+11.45%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$76M
AUM Growth
-$11.1M
(-13%)
Cap. Flow
+$112M
Cap. Flow
% of AUM
147.28%
Top 10 Holdings %
Top 10 Hldgs %
38.02%
Holding
408
New
159
Increased
53
Reduced
54
Closed
131
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$3.17M |
| 2 |
K
Kellanova
K
|
+$2.19M |
| 3 |
FL
Foot Locker
FL
|
+$2.04M |
| 4 |
General Mills
GIS
|
+$1.95M |
| 5 |
lululemon athletica
LULU
|
+$1.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$9.7M |
| 2 |
JPMorgan Chase
JPM
|
+$3.58M |
| 3 |
Gilead Sciences
GILD
|
+$3.38M |
| 4 |
Constellation Brands
STZ
|
+$2.74M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.66% |
| 2 | Consumer Staples | 16.16% |
| 3 | Consumer Discretionary | 9.31% |
| 4 | Communication Services | 3.38% |
| 5 | Materials | 2.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
PUT
Mondelez International
MDLZ
$78.3B
| $130K | 0.17% |
70,100
-27,100
| -28% | -$1.2M |
|
|
GWPH
102
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $125K | 0.16% |
9,100
-120,100
| -93% | -$14.7M |
|
|
APC
103
PUT
DELISTED
Anadarko Petroleum
APC
| $125K | 0.16% |
+12,000
| New | +$798K |
|
|
FOLD
104
CALL
DELISTED
Amicus Therapeutics
FOLD
| $123K | 0.16% |
81,800
+54,600
| +201% | +$345K |
|
105
CALL
NVIDIA
NVDA
$4.91T
| $122K | 0.16% |
920,000
+520,000
| +130% | +$1.38M |
|
|
106
PUT
Regeneron Pharmaceuticals
REGN
$70.9B
| $122K | 0.16% |
3,500
-97,600
| -97% | -$36.2M |
|
107
PUT
Clorox
CLX
$11.6B
| $120K | 0.16% |
39,200
+8,000
| +26% | +$1.04M |
|
108
CALL
Johnson & Johnson
JNJ
$609B
| $120K | 0.16% |
+53,000
| New | +$6.33M |
|
109
Nektar Therapeutics
NKTR
$2.31B
| $120K | 0.16% |
+340
| New | +$76.4K |
|
110
Papa John's
PZZA
$1.08B
| $120K | 0.16% |
1,500
-1,691
| -53% | -$138K |
|
111
DaVita
DVA
$15.2B
| $116K | 0.15% |
+1,700
| New | +$113K |
|
|
ZSAN
112
DELISTED
Zosano Pharma Corporation
ZSAN
| $114K | 0.15% |
+86
| New | +$104K |
|
113
PUT
Incyte
INCY
$23.4B
| $110K | 0.14% |
+9,000
| New | +$1.15M |
|
114
PUT
iShares Biotechnology ETF
IBB
$9.23B
| $101K | 0.13% |
+66,000
| New | +$6.32M |
|
115
CALL
Royal Gold
RGLD
$16.1B
| $99K | 0.13% |
+20,500
| New | +$1.39M |
|
|
116
CALL
Papa John's
PZZA
$1.08B
| $96K | 0.13% |
19,000
-400
| -2% | -$32.5K |
|
|
BWLD
117
PUT
DELISTED
Buffalo Wild Wings, Inc.
BWLD
| $94K | 0.12% |
+15,200
| New | +$2.32M |
|
118
CALL
Acadia Pharmaceuticals
ACAD
$4.38B
| $91K | 0.12% |
10,200
| – | – |
|
119
PUT
Insmed
INSM
$23.5B
| $91K | 0.12% |
+85,000
| New | +$1.31M |
|
|
CLVS
120
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $89K | 0.12% |
+13,500
| New | +$821K |
|
121
CALL
Exelixis
EXEL
$14.1B
| $87K | 0.11% |
20,000
-151,900
| -88% | -$3.09M |
|
122
CALL
Sprouts Farmers Market
SFM
$7.13B
| $87K | 0.11% |
+31,100
| New | +$609K |
|
123
PUT
Walt Disney
DIS
$170B
| $86K | 0.11% |
+35,000
| New | +$3.85M |
|
|
124
NVIDIA
NVDA
$4.91T
| $85K | 0.11% |
31,080
-128,920
| -81% | -$343K |
|
125
PUT
Alibaba
BABA
$276B
| $84K | 0.11% |
13,000
-100
| -0.8% | -$10.2K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2017 Portfolio in Review
As of Q1 2017, FT Options held 408 positions worth $76M, down 13% from $87.1M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $112M of net new capital in Q1 2017, opening 159 new positions and adding to 53 existing holdings. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 45% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $9.7M trimmed.
- FT Options's largest Q1 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
- FT Options added most to Kellanova in Q1 2017, an estimated $2.19M increase.
- FT Options's biggest Q1 2017 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.7M.
- FT Options fully exited JPMorgan Chase in Q1 2017, selling an estimated $3.58M.
- FT Options's ten largest holdings make up 38% of its $76M portfolio in Q1 2017.
- FT Options opened 159 new positions and closed 131 in Q1 2017.
- FT Options's portfolio value fell 13% quarter-over-quarter to $76M.
Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.